Radiation-induced lung fibrosis (RILF) is a common complication of radiotherapy in lung cancer. However, to date no effective treatment has been developed for this condition. NXC736 is a novel small-molecule compound that inhibits NLRP3, but its effect on RILF is unknown. NLRP3 activation is an important trigger for the development of RILF. Thus, we aimed to evaluate the therapeutic effect of NXC736 on lung fibrosis inhibition using a RILF animal model and to elucidate its molecular signaling pathway. The left lungs of mice were irradiated with a single dose of 75 Gy. We observed that NXC736 treatment inhibited collagen deposition and inflammatory cell infiltration in irradiated mouse lung tissues. The damaged lung volume, evaluated by magnetic resonance imaging, was lower in NXC736-treated mice than in irradiated mice. NXC736-treated mice exhibited significant changes in lung function parameters. NXC736 inhibited inflammasome activation by interfering with the NLRP3-ASC-cleaved caspase-1 interaction, thereby reducing the expression of IL-1β and blocking the fibrotic pathway. In addition, NXC736 treatment reduced the expression of epithelial–mesenchymal transition markers such as α-SMA, vimentin, and twist by blocking the Smad 2,3,4 signaling pathway. These data suggested that NXC736 is a potent therapeutic agent against RILF.
In a recent stereotactic body radiation therapy animal model, radiation pneumonitis and radiation pulmonary fibrosis were observed at around 2 and 6 weeks, respectively. However, the molecular signature of this model remains unclear. This study aimed to examine the molecular characteristics at these two stages using RNA-seq analysis. Transcriptomic profiling revealed distinct transcriptional patterns for each stage. Inflammatory response and immune cell activation were involved in both stages. Cell cycle processes and response to type II interferons were observed during the inflammation stage. Extracellular matrix organization and immunoglobulin production were noted during the fibrosis stage. To investigate the impact of a 10 Gy difference on fibrosis progression, doses of 45, 55, and 65 Gy were tested. A dose of 65 Gy was selected and compared with 75 Gy. The 65 Gy dose induced inflammation and fibrosis as well as the 75 Gy dose, but with reduced lung damage, fewer inflammatory cells, and decreased collagen deposition, particularly during the inflammation stage. Transcriptomic analysis revealed significant overlap, but differences were observed and clarified in Gene Ontology and KEGG pathway analysis, potentially influenced by changes in interferon-gamma-mediated lipid metabolism. This suggests the suitability of 65 Gy for future preclinical basic and pharmaceutical research connected with radiation-induced lung injury.
Background: Radiation-induced pulmonary fibrosis (RPF) remains a major burden of successful lung cancer radiotherapy. Clinically validated drugs targeting RPF remains scarce. Methods: We employed a transcriptome-based drug repurposing approach using REMEDY, a computational platform built on the Library of Integrated Network-Based Cellular Signatures (LINCS). Differentially expressed genes (DEGs) derived from radiation-induced lung injury (RILI) models were used as a query to identify compounds capable of reversing pro-fibrotic expression profile. Among top-ranked candidates, homoharringtonine (HHT), an FDA-approved protein synthesis inhibitor, was selected for experimental validation. Anti-fibrotic effects of HHT were assessed using an optimized in vitro fibrotic model based on activation of MRC-5 human lung fibroblasts. Complementary in silico molecular docking analyses were also conducted to explore the mechanistic basis of HHT’s actions. This represents the first transcriptome-guided, LINCS-based drug repurposing study applied specifically to radiation-induced pulmonary fibrosis, utilizing RPF-derived molecular signatures rather than general fibrosis-related datasets. Results: HHT significantly attenuated key fibrotic phenotypes, including fibroblast proliferation, myofibroblast differentiation, and extracellular matrix (ECM) production. Notably, HHT suppressed expression of cyclin D1 and α-smooth muscle actin (α-SMA), and reduced collagen deposition. Mechanistic investigations revealed that HHT modulates two pro-fibrotic pathways: RhoA/ROCK and Wnt/β-catenin signaling. Molecular docking further suggested that HHT may directly interact with fibrosis-related receptors such as integrins and Frizzled, providing structural insight into its anti-fibrotic potential. These findings underscore the novelty of reassigning HHT to a radiation-specific fibrotic context using a signature-reversal strategy uniquely tailored to RPF biology. Conclusions: Our findings identify HHT as a promising treatment of RPF, offering a dual mechanism of action—interruption of protein synthesis and targeted inhibition of fibrotic signaling pathways. This study highlights the value of computational drug repurposing platforms for accelerating therapeutic discovery. Further preclinical investigations are warranted to evaluate HHT’s in vivo efficacy and clinical applicability in RPF.
Radiation-induced lung inflammation (RILI) is a major complication of thoracic radiotherapy, characterized by excessive inflammation and subsequent fibrosis that compromise pulmonary function and treatment outcomes. This study explores the pharmacological properties of a newly synthesized Lipoxin A4 analogue (CYNC-2) to mitigate RILI by modulating the AMP-activated protein kinase (AMPK)/NOD-like receptor family pyrin domain containing 3(NLRP3) inflammasome pathway. A murine RILI model was established in mice by delivering a single high-dose (ablative) X-ray irradiation to the left lung. Mice in the treatment group received CYNC-2 via tail-vein injection three times per week for 2 weeks. The effects of CYNC-2 on RILI were evaluated histological, immunohistochemical analysis of lung tissues, cytokine profiling, lung function testing using a FlexiVent system, and micro-computed tomography (micro-CT) imaging of lung damage. In parallel, two human lung cell lines—L132 (normal bronchial epithelial cells) and A549 (lung carcinoma cells)—were irradiated with 6 Gy X-rays and treated with CYNC-2 to assess cell viability and changes in AMPK/NLRP3 pathway markers via qPCR and immunofluorescence. Lung tissue sample from patients who underwent thoracic radiotherapy were also examined to validate key findings. CYNC-2 activated AMPK and inhibited mTOR signaling, which suppressed NLRP3 inflammasome activation and led to reduced secretion of pro-inflammatory cytokines (IL-1β, IL-6, and TGF-β1). In vitro, CYNC-2 mitigated radiation-induced inflammatory responses and preserved cellular viability. Overall, CYNC-2 effectively dampened acute pulmonary in the RILI model. These findings suggest that targeting the AMPK/NLRP3 inflammasome pathway via a stable LXA4 analogue such as CYNC-2 is a promising therapeutic strategy to improve clinical outcomes for patients receiving thoracic radiation therapy.
Brachytherapy-integrated hyperthermia combines implant-based radiation delivery with localized heating, but the evidence spans heterogeneous diseases, devices, temperature measurements, and study designs. We conducted a systematic search-based evidence map with revision-stage record reconciliation, human adjudication, report-to-study linkage, and design-matched clinical appraisal. Of 8189 unique records screened in the original search, 2178 candidate or uncertain records underwent documented revision-stage human adjudication. During acceptance-stage revision, all 3919 records originally assigned to the machine exclusion stratum also received a primary human title/abstract re-screen decision; 3916 exclusions were confirmed and three boundary records were reclassified. The final unified worklist comprised 285 records. Ninety-two verified/supporting report units were adjudicated (15 direct clinical, 34 technical/platform, 24 supporting, and 19 excluded). The 15 core clinical reports represented 14 independent studies and generated 17 appraisal records using RoB 2, ROBINS-I, and JBI tools. Two randomised phase III trials did not show improved disease control or survival with added hyperthermia; both were judged to raise some concerns for risk of bias, and both had important thermal intervention limitations. One non-randomised cervical comparison was at serious risk of bias from confounding by indication. Uncontrolled prostate, anal, gynaecologic, and mixed pelvic series supported procedural feasibility but not causal efficacy. Two predefined supplemental saturation batches added no new eligible evidence in any family or domain. The evidence supports standardised multipoint thermometry, measurement-anchored spatial reconstruction, coupled planning, platform qualification, and disease-specific trials only after thermal fidelity gates are passed.
Background/Objectives: Radiation-induced lung injury (RILI) involves inflammatory responses followed by fibrotic remodeling. We evaluated CYNC-1, a synthetic compound designed as a lipoxin A4 (LXA4) mimetic, for chemical stability, cellular activity, and attenuation of lung injury after irradiation. Methods: HeLa-derived L132 epithelial-like cells and THP1-Lucia NF-κB reporter monocytes were used for cell-based assays. Male C57BL/6 mice received a single 75-Gy focal lung irradiation. CYNC-1 administration began immediately after irradiation and continued every other day for 2 or 6 weeks. Lung injury was assessed using bronchoalveolar lavage fluid cellularity, micro-computed tomography, histopathology, and lung mechanics. Prednisolone and nintedanib served as reference treatments in the 2- and 6-week cohorts, respectively. Results: CYNC-1 maintained high HPLC area purity during light-protected ethanol storage for 48 h at −78, −20, and 4 °C. It increased survival of irradiated L132 cells and reduced LPS-induced NF-κB reporter activity. In L132 cells, treatment was associated with reduced NF-κB/MAPK and Smad2 phosphorylation and lower profibrotic marker expression. In mice, CYNC-1 reduced inflammatory cell accumulation and collagen deposition and improved lung structure and mechanics. Conclusions: Early and continued CYNC-1 administration attenuated lung inflammation and subsequent fibrotic remodeling in this focal irradiation model. The signaling findings are associative, and FPR2 dependence and efficacy against established fibrosis remain to be established. Validation in primary human lung cells, clinically relevant fractionated irradiation models, animals of both sexes, and tumor models is needed to determine suitability as a normal-tissue protectant, including preservation of antitumor efficacy.